Libenzapril

Libenzapril (Abutapril; CGS-16617) is an orally active, potent direct-acting angiotensin-converting-enzyme (ACE) inhibitor. Libenzapril has the potential for ischemia-induced heart failure research[1].

Product Specifications

CAS Number

[109214-55-3]

Product Name Alternative

Abutapril; CGS-16617

UNSPSC

12352005

Target

Angiotensin-converting Enzyme (ACE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/libenzapril.html

Smiles

O=C1N(C2=CC=CC=C2CC[C@@H]1N[C@H](C(O)=O)CCCCN)CC(O)=O

Molecular Formula

C18H25N3O5

Molecular Weight

363.41

References & Citations

[1]E F Smith 3rd, et al. Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat. Pharmacology. 1988;37 (4) :254-63.